Zai Lab (HKSE:09688) Land And Improvements : HK$0 Mil (As of Mar. 2025)

View and export this data going back to 2020. Start your Free Trial

What is Zai Lab Land And Improvements?

Zai Lab's land and improvements for the quarter that ended in Mar. 2025 was HK$0 Mil.

Zai Lab Land And Improvements Historical Data

The historical data trend for Zai Lab's Land And Improvements can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zai Lab Land And Improvements Chart

Zai Lab Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Land And Improvements

Get a 7-Day Free Trial

Zai Lab Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Land And Improvements	Get a 7-Day Free Trial															-	-	-	-	-

Zai Lab Land And Improvements Calculation

Land is the surface or crust of the earth, which can be used to support structures, and may be used to grow crops, grass, shrubs, and trees. Land is characterized as having an unlimited life (indefinite). Land improvement is a long-term asset which indicates the cost of the constructed improvements to land, such as driveways, walkways, lighting, and parking lots.

Zai Lab Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zai Lab Ltd (HKSE:09688) » Definitions » Land And Improvements

Comparable Companies

Traded in Other Exchanges

ZLAB:USA ZLAB N:Mexico 1ZLB:Germany 1ZLB:Germany 1ZL:Germany 1ZL:Germany

Address

4560 Jinke Road, Jinchuang Plaza, Building 1, 4th Floor, Pudong, Shanghai, CHN, 201210

Website

https://www.zailaboratory.com

Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-1218 (CCR8) Solid Tumors, ZL-1310 (DLL3 ADC) ES-SCLC Other NECs, ZL-6301 (ROR1 ADC) Solid Tumors, ZL 6201 (LRRC15 ADC) Solid Tumors.

Executives

Fmr Llc	2201 Interest of corporation controlled by you
Jpmorgan Chase & Co.	2201 Interest of corporation controlled by you
Du Ying	2101 Beneficial owner
The Capital Group Companies, Inc.	2201 Interest of corporation controlled by you
Wellington Management Group Llp	2102 Investment manager
Janus Henderson Group Plc	2102 Investment manager
Ubs Group Ag	2201 Interest of corporation controlled by you
Qiming Corporate Gp Iv, Ltd.
Qiming Gp Iv, L.p.
Qiming Venture Partners Iv, L.p.
Qm11 Limited
Invesco Advisers, Inc.	2102 Investment manager
Invesco Developing Markets Fund	2106 Person having a security interest in shares
Baillie Gifford & Co	2102 Investment manager
Citigroup Inc.	2502 Approved lending agent

Zai Lab Headlines

No Headlines